Navigation Links
The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market
Date:2/7/2013

BURLINGTON, Mass., Feb. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expected supplemental approval of Millennium (Takeda)/Johnson & Johnson's Velcade for the treatment of chronic graft versus host disease (GVHD) will be a significant driver of growth in the GVHD market through 2021. In particular, Velcade's uptake in the first-line treatment setting will displace lower-priced standards of care such as corticosteroids and small-molecule immunosuppressants.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to Niche Markets and Rare Diseases: Graft Versus Host Disease, expert physicians report that Velcade's market potential could be even greater, based on their interest in employing Velcade in the prophylactic setting. The market opportunity for prophylactic therapies, based on underlying population sizes, is up to three times larger than for primary or later-line treatments.

The report also finds that although the current clinical pipeline is sparse, several drug developers have nevertheless been drawn into GVHD drug development by the potential to secure orphan-drug designation for novel agents.

"GVHD is an excellent illustration of the orphan drug designation working effectively -- without the benefits of the orphan designation, companies might be reluctant to develop drugs for such a small, specific population," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D.

GVHD is a relatively rare condition that occurs in a patient population -- severely ill oncology patients eligible for hematopoietic stem cell transplant -- who already have access to costly specialized treatment. Interviewed hematologist/oncologists report that cost concerns have little to no impact on current treatment decisions, and do not anticipate major changes in payers' attitudes toward GVHD reimbursement following launches of novel therapies.

About Graft Versus Host Disease
Graft Versus Host Disease is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
3. Global Bioinformatics Market is Expected to Reach USD 9.1 Billion in 2018: Transparency Market Research
4. Global Ostomy Drainage Bags Market is Expected to Reach USD 2.6 Billion in 2018: Transparency Market Research
5. Global High Potency Active Pharmaceutical Ingredients (HPAPIs) Market is Expected to Reach USD 17.5 billion in 2018: Transparency Market Research
6. Global Neuromodulation Devices Market is Expected to Reach USD 7,072.6 Million in 2018: Transparency Market Research
7. Global ECG Monitoring Systems Market is Expected to Reach USD 822.1 Million in 2016: Transparency Market Research
8. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
9. U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research
10. Global Laparoscopy Devices Market is Expected to Reach USD 13,152.9 Million in 2018: Transparency Market Research
11. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):